U.S. markets closed
  • S&P 500

    4,512.91
    -54.09 (-1.18%)
     
  • Dow 30

    34,021.61
    -462.11 (-1.34%)
     
  • Nasdaq

    15,254.05
    -283.64 (-1.83%)
     
  • Russell 2000

    2,171.62
    -27.29 (-1.24%)
     
  • Crude Oil

    65.35
    -0.83 (-1.25%)
     
  • Gold

    1,780.50
    +4.00 (+0.23%)
     
  • Silver

    22.22
    -0.60 (-2.63%)
     
  • EUR/USD

    1.1317
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • GBP/USD

    1.3268
    -0.0033 (-0.25%)
     
  • USD/JPY

    112.8180
    -0.3620 (-0.32%)
     
  • BTC-USD

    56,827.82
    -687.18 (-1.19%)
     
  • CMC Crypto 200

    1,446.25
    -22.83 (-1.55%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Why Mirati Therapeutics Stock Is Trading Higher Today

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday after the company announced clinical data with investigational adagrasib as monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.

"These positive topline data further strengthen our belief in adagrasib as a potentially differentiated therapy for patients with non-small cell lung cancer harboring the KRAS G12C mutation. We look forward to submitting our New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2021 and advancing our expanding adagrasib development program, which includes numerous monotherapy and combination studies in KRAS G12C-mutated solid tumors," said Charles Baum, president and CEO of Mirati Therapeutics.

Mirati Therapeutics is an American biotechnology company focused on precision medicine.

MRTX Price Action: Mirati Therapeutics has traded as high as $249.42 and as low as $131.46 over a 52-week period.

The stock was up 5.10% at $182.92 at time of publication.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.